Targeted Therapies Continue to Shift Treatment Armamentarium in Multiple Myeloma
August 26th 2022
Patient outcomes across the multiple myeloma landscape have vastly improved with the approval of multiple agents in the treatment armementarium, such as belantamab mafodotin-blmf, selinexor, and ciltacabtagene autoleucel.